EVH vs TOI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EVH exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a significant YoY revenue decline of 27.50%. While the stock trades at a low Price-to-Book (0.84) and Price-to-Sales (0.19) ratio, these metrics likely represent a value trap given the negative profit margins (-28.49%) and high debt-to-equity ratio (2.38). Despite a 'Strong Buy' analyst consensus and a target price of $5.18, the deterministic data and long-term price performance (-85.2% over 5 years) suggest a high-risk profile with failing operational momentum.
The Oncology Institute (TOI) exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price/Book ratio of -22.14, indicating negative shareholders' equity. While the company shows impressive top-line revenue growth of 41.60% YoY, it remains unprofitable with negative operating and profit margins. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual financial health and bearish insider selling patterns. The lack of a Graham Number or Altman Z-Score further underscores the company's distressed financial state.
Compare Another Pair
Related Comparisons
EVH vs TOI: Head-to-Head Comparison
This page compares Evolent Health, Inc. (EVH) and The Oncology Institute, Inc. (TOI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.